2025年阿福他酶α最新价格是多少钱一盒？

Afotalase α is an enzyme replacement therapy drug used to treat hypophosphatasia (HPP). It is developed by Alexion Pharmaceuticals (Alexion) of the United States and its trade name is Strensiq. The latest data in 2025 shows that the price of 18mg/0.45mL/box of aftase alpha is approximately US$13,205, which is relatively high and has not yet been officially approved for marketing in China. The drug has been approved in many countries including Europe and the United States, and has shown significant clinical efficacy, significantly improving the survival rate and bone development of patients with hypophosphatasia.

What is the latest price of a box of Aftase α in 2025?

The original drug is produced by Ruisong Pharmaceuticals in the United States. The latest price information in 2025 shows that the price of 18mg/0.45mL/box is approximately US$13,205. Since the drug has not yet been officially launched in the country, patients need to purchase it through overseas channels.

Price of 18mg/0.45mL specifications

The price of 18mg/0.45mL/box of aftase alpha is approximately US$13,205. It is suitable for adult standard dose treatment and requires 2-3 boxes per month. Long-term treatment costs are high and imposes a greater financial burden on patients.

Price of other specifications

Afotalase α is also available in 28mg/0.7mL, 40mg/mL and 80mg/0.8mL. The price varies depending on the specifications. The 80mg/0.8mL specification is suitable for patients with larger body weight, but is prohibited for patients weighing less than 40kg.

The high price of aftase alpha limits its widespread application worldwide, and patients are looking forward to more economical alternative treatment options in the future.

Global marketing status of aftase α

Aftase α has been approved for marketing in many countries and regions, but as of June 2025, it has not been officially approved in mainland China.

Marketing status in Europe, the United States and Japan

Afotalase α was approved for marketing in the United States in 2015, and was subsequently approved in many countries and regions such as Europe and Japan. The drug has become the standard treatment for hypophosphatasia worldwide.

Domestic Approval Progress

Many domestic medical institutions are conducting clinical research on aftase α to evaluate its efficacy and safety in Chinese patients. These data will support future formal marketing applications for the drug.

With the increasing attention paid to rare diseases in China, aftase alpha is expected to be officially approved in the near future, benefiting more Chinese patients.

Preparation for the administration of aftase α

Afotalase α must be used strictly in accordance with the doctor's instructions. The following are the key preparations for medication.

Dose calculation and adjustment

The recommended dose is 6 mg/kg per week, which can be divided into subcutaneous injections of 2 mg/kg three times per week or 1 mg/kg six times per week. If efficacy is insufficient, the dose can be increased to 9 mg/kg per week.

Injection method and storage

Afotalase α needs to be refrigerated at 2-8°C and avoid freezing or direct sunlight. It needs to be taken out of the refrigerator and used within 3 hours before injection. The injection site should be rotated (abdomen, thighs, upper arms, etc.) to avoid fat atrophy.

The use of aftase alfa must be carried out under the guidance of experienced medical professionals. Patients are not allowed to adjust the dosage or injection method by themselves.